Improvement of Cardiac Function after Granulocyte-colony Stimulating Factor-mobilized Peripheral Blood Mononuclear Cell Implantation in a Patient with Non-ischemic Dilated Cardiomyopathy Associated with Thromboangiitis Obliterans

Kakihana, Ayano; Ishida, Akio; Miyagi, Megumi; Ishiki, Tetsuya; Okumura, Koichiro; Kamiyama, Tomomasa; Ohya, Yusuke; Takishita, Shuichi

doi:10.2169/internalmedicine.48.2117

Cited by 6 publications

(6 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their report suggested that peripheral blood mononuclear implantation with GCSF could be an effective approach to treating nonischemic heart failure, though the exact mechanisms of improved cardiac function are still unclear [15]. …”

Section: Discussionmentioning

confidence: 99%

“…The best scenario of mobilized cell fate is that cells differentiate into functioning cardiomyocytes within a failing heart, replacing damaged cardiomyocytes. However, studies have shown that rate of cardiomyocyte differentiation from stem cells is low and the mobilized cells are involved in angiogenesis and host cardiomyocyte regeneration via direct cell differentiation and/or paracrine effects that secrete various growth factors and/or cytokines [15]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Role of Mobilized Bone Marrow Cells in Children with Nonischemic Dilated Cardiomyopathy

2012

View full text Add to dashboard Cite

Dilated cardiomyopathy is an important cause of congestive cardiac failure in infants and children. Mobilizing hematopoietic progenitor cells is a promising intervention to this deadly disease. Aim. Evaluate granulocyte colony stimulating factor (GCSF) as therapeutic modality in children with idiopathic dilated cardiomyopathy (IDCM). Subjects and Methods. This case-control prospective study was conducted on 20 children with IDCM following up at Cardiology Clinic Children's Hospital, Ain Shams University (group 1) who were compared to another 10 age-, sex-, duration-of-illness-, and systolic-function-matched children with IDCM as control (group 2). They were subjected to history taking, clinical examination, echocardiography, and peripheral blood CD34+ cell assessment before and one week after GCSF intake for 5 consecutive days (by group 1 but not group 2). Results. A significant improvement in echocardiographic data and CD34+-T-cell increase was found in group 1 one week after GCSF intake and for the next 6 months CD34+ T cells percentage of change showed no significant correlation with the that of the left ventricular dimensions and systolic function. Conclusion. Administration of GCSF to children with IDCM resulted in clinical and echocardiographic improvement not correlated to mobilized CD34+ T cells, implying involvement of additional mechanisms over simple stem cell mobilization.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Therapeutic Role of Mobilized Bone Marrow Cells in Children with Nonischemic Dilated Cardiomyopathy

2012

View full text Add to dashboard Cite

show abstract

“…ABMSCT is a promising and prospective approach in the treatment of severe peripheral arterial disorders, in particular in Buerger's disease. All of the published clinical trials have reported on the affectivity and safety of ABMSCT in Buerger's disease even though the variation of the cell populations and protocols used for the therapy [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. It is well established that the bone marrow contains multiple stem-and progenitor cells with the potential to support vessel regeneration.…”

Section: Discussionmentioning

confidence: 99%

“…Buerger's disease [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. However, very little information is available on the duration of the beneficial effect of SCT [12], and according to our best knowledge no data exist on the efficacy and safety of repeated SCT carried out in patients with relapsing or worsening clinical states in severe Buerger's disease.…”

Section: Introductionmentioning

confidence: 99%

Repeated application of autologous bone marrow-derived stem cell therapy in patients with severe Buerger’s disease

Boda¹,

Rázsó²,

Szarvas³

et al. 2011

SCD

View full text Add to dashboard Cite

Stem cell therapy (SCT) is a promising and prospective approach in the treatment of patients with severe peripheral arterial disorders, primarily with Buerger's disease. However, very little is known about the duration of the effect of SCT, and to our best knowledge no data are available on the efficacy and safety of repeated SCT in patients with Buerger's disease. Here we report on two patients with severe Buerger's disease, who received repeated autologous bone marrow-derived stem cell therapy. Our results show that a second SCT, applied to a previously treated leg 30 or 36 months after the first treatment was efficient in both cases. After twelve months, the clinical state of the repeatedly treated lower limb improved spectacularly and non-healing ulcers healed more rapidly than after the first SCT. No severe adverse events were detected. Thus repeated SCT offers a safe and efficient treatment option for relapsing patients at the advanced stage of Buerger's disease.

show abstract

“…The acuity of ischemic limbs seems to be a limiting factor, and recipients with Buerger's disease may be more favorable than those with ASO. 29) In any case, early cell transplantation therapy is recommended as an optional treatment for selected patients with peripheral arterial disease.…”

Section: Pathophysiological Factors Influencing the Efficacy And Safementioning

confidence: 99%

Autologous Peripheral Blood-Derived Mononuclear Cells Induced by Erythropoietin Improve Critical Ischemic Limbs

Kanbara

Kurobe

Kitaichi

et al. 2012

Annals of Vascular Diseases

View full text Add to dashboard Cite

Purpose: Efficient and secure collection of CD34+ cells are crucial for the angiogenic therapies. We have developed autologous peripheral blood-mononuclear cell (MNC) transplantation induced by erythropoietin (rhEPO) for critical ischemic limbs. Methods: Seven patients, including five with arteriosclerosis obliterans, one with Buerger's disease and one with progressive systemic sclerosis, underwent ten cell therapies. The first administration of rhEPO was performed two weeks before apheresis, and the second administration and blood donation were performed one week before apheresis to activate bone marrow. MNCs including CD34+ cells, isolated from peripheral blood by apheresis, were immediately injected intramuscularly into ischemic limbs. Results: The number of peripheral blood-CD34 + cells had significantly increased from 1.32 ± 0.83/microL, before the rhEPO induction, to 1.86 ± 0.94/microL, before the apheresis. The number of transplanted MNCs ranged between 0.5 × 10 9 and 16.5 × 10 9 , and that of CD34+ cells, between 0.1 × 10 6 and 12.7 × 10 6 , accounting for 0.02%-0.1% of MNCs. There were no serious complications. Finger ulcers with Buerger's disease were significantly improved one month after the transplantations, but the same or other ulcer(s) appeared 2-6 months later. Three patients had an improvement in rest pain, and one patient extended maximum pain-free walking distance. Conclusions: Erythropoietin-induced autologous peripheral blood-MNC transplantation is a useful and safe alternative for ischemic limbs.

show abstract

Improvement of Cardiac Function after Granulocyte-colony Stimulating Factor-mobilized Peripheral Blood Mononuclear Cell Implantation in a Patient with Non-ischemic Dilated Cardiomyopathy Associated with Thromboangiitis Obliterans

Abstract: Cardiac involvement is a rare complication with thromboangiitis obliterans (TAO

Cited by 6 publications

References 27 publications

Therapeutic Role of Mobilized Bone Marrow Cells in Children with Nonischemic Dilated Cardiomyopathy

Therapeutic Role of Mobilized Bone Marrow Cells in Children with Nonischemic Dilated Cardiomyopathy

Repeated application of autologous bone marrow-derived stem cell therapy in patients with severe Buerger’s disease

Autologous Peripheral Blood-Derived Mononuclear Cells Induced by Erythropoietin Improve Critical Ischemic Limbs

Contact Info

Product

Resources

About